search
Back to results

Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure

Primary Purpose

Short Gut Syndrome

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Sucrase
Placebo
Sponsored by
University of Miami
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Short Gut Syndrome focused on measuring Intestinal failure

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Short bowel syndrome, of all ages, with dependence on parental support to provide at least 50% of fluid or caloric needs.
  • Must be on diet containing sucrose.
  • Must be willing and able to sign informed consent
  • Adult and Pediatric patients (all ages)

Exclusion Criteria:

  • Current IV antibiotic administration for confirmed bout of bacteremia.
  • No enteral nutrition
  • Any condition, disease, illness, or circumstance that in the investigator's opinion puts the subject at any undue risk, prevents completion of the study, or interferes with analysis of the study results

Sites / Locations

  • Jackson Memorial HospitalRecruiting
  • University of Miami

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Sucrase intervention followed by placebo

Placebo followed by sucrase intervention

Arm Description

Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.

Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.

Outcomes

Primary Outcome Measures

Change in Carbohydrate Malabsorption
Degree of carbohydrate malabsorption will be assessed by decrease in number of stools per day.
Change in Carbohydrate Malabsorption as measured by patient symptom survey
Degree of carbohydrate malabsorption will be assessed by change in patient symptomatology by change in score on patient symptom survey. The survey has range from 0-52 with higher score being worse symptoms and lower being better.
Change in Carbohydrate Malabsorption as measured by growth velocity
Carbohydrate malabsorption will be measured by increase in growth velocity in kg/week
Change in Carbohydrate Malabsorption as measured by enteral nutrition tolerance
Carbohydrate malabsorption will be measured by ability to advance enteral nutrition in ml/day

Secondary Outcome Measures

Change in digestion
Change in digestion will be measured by change in abdominal distension/girth measured in cm
Change in digestion as measured by amount of emesis
Change in digestion will be assessed by number of emesis per day
Change in digestion as measured by stool consistency
Change in digestion will be assessed as a change in stool consistency from liquid (7) to solid(1) using Bristol stool chart

Full Information

First Posted
October 22, 2020
Last Updated
October 27, 2022
Sponsor
University of Miami
Collaborators
QOL Medical, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04604275
Brief Title
Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure
Official Title
Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 2, 2022 (Actual)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Miami
Collaborators
QOL Medical, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. This can happen due to loss of bowel length from surgery or from loss of cellular function in the intestines due to use of parenteral nutrition intravenously. Therefore, patients with these conditions may not be able to digest sucrose (sugar) fully. Patients might experience abdominal distension/pain, vomiting and diarrhea when sugar is taken in orally or through the g-tube, which can limit patients' ability to increase oral or g-tube feeds in short gut syndrome patients with intestinal failure. In patients with short gut syndrome and intestinal failure, the administration of exogenous sucrase (enzyme) may improve sucrose (sugar) digestion and thus the ability to tolerate more oral or g-tube feeds.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Short Gut Syndrome
Keywords
Intestinal failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sucrase intervention followed by placebo
Arm Type
Experimental
Arm Description
Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
Arm Title
Placebo followed by sucrase intervention
Arm Type
Experimental
Arm Description
Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.
Intervention Type
Drug
Intervention Name(s)
Sucrase
Intervention Description
1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
Primary Outcome Measure Information:
Title
Change in Carbohydrate Malabsorption
Description
Degree of carbohydrate malabsorption will be assessed by decrease in number of stools per day.
Time Frame
baseline, up to 9 weeks
Title
Change in Carbohydrate Malabsorption as measured by patient symptom survey
Description
Degree of carbohydrate malabsorption will be assessed by change in patient symptomatology by change in score on patient symptom survey. The survey has range from 0-52 with higher score being worse symptoms and lower being better.
Time Frame
baseline, up to 9 weeks
Title
Change in Carbohydrate Malabsorption as measured by growth velocity
Description
Carbohydrate malabsorption will be measured by increase in growth velocity in kg/week
Time Frame
baseline, up to 9 weeks
Title
Change in Carbohydrate Malabsorption as measured by enteral nutrition tolerance
Description
Carbohydrate malabsorption will be measured by ability to advance enteral nutrition in ml/day
Time Frame
baseline, up to 9 weeks
Secondary Outcome Measure Information:
Title
Change in digestion
Description
Change in digestion will be measured by change in abdominal distension/girth measured in cm
Time Frame
baseline, up to 9 weeks
Title
Change in digestion as measured by amount of emesis
Description
Change in digestion will be assessed by number of emesis per day
Time Frame
baseline, up to 9 weeks
Title
Change in digestion as measured by stool consistency
Description
Change in digestion will be assessed as a change in stool consistency from liquid (7) to solid(1) using Bristol stool chart
Time Frame
baseline, up to 9 weeks

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Short bowel syndrome, of all ages, with dependence on parental support to provide at least 50% of fluid or caloric needs. Must be on diet containing sucrose. Must be willing and able to sign informed consent Adult and Pediatric patients (all ages) Exclusion Criteria: Current IV antibiotic administration for confirmed bout of bacteremia. No enteral nutrition Any condition, disease, illness, or circumstance that in the investigator's opinion puts the subject at any undue risk, prevents completion of the study, or interferes with analysis of the study results
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amanda Fifi, MD
Phone
3052433166
Email
afifi@med.miami.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Cara Axelrod, RD
Phone
3052433166
Email
cxa630@med.miami.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amanda Fifi, MD
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jackson Memorial Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Fifi, MD
Phone
305-243-3166
Email
afifi@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Cara Axelrod, MD
Phone
3052433166
Email
cxa630@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Amanda Fifi, MD
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Fifi, MD
Phone
305-243-3166
Email
afifi@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Cara Axelrod, RD
Phone
3052433166
Ext
FIFI
Email
amandacfifi@gmail.com
First Name & Middle Initial & Last Name & Degree
AMANDA FIFI, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure

We'll reach out to this number within 24 hrs